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were females. The mean age and Charlson Co-morbidity Index
score were higher among patients who received INF compared
to those on ETA. All-cause PPPM costs were higher among
patients who received ETA ($6320) compared to patients who
received INF ($2313). The magnitude of the difference was
greater among patients who received INF alone ($3368) com-
pared to ETA alone ($8257, p < 0.05). Differences in total health
care costs persisted after adjustment for covariates (p = 0.0366).
Similar results were obtained when excluding outlier patients
with high cost (outliers were deﬁned as those patients with values
more than 2 standard deviations above the mean). CONCLU-
SION: This study indicates that INF therapy is associated with
lower all cause health care costs compared to ETA therapy, in
the treatment of patients with PsA. The choice of a biologic treat-
ment on health care costs should be considered when evaluating
treatment strategies.
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OBJECTIVES: To evaluate trends in utilization and cost of phar-
macologic treatments of osteoarthritis (OA). METHODS: A ret-
rospective analysis of OA patients (>18 years of age) in the
PHARMetrics database during 2001 and 2002 was conducted
using an observation period (January 2003–June 2005) divided
into ten quarters. Patients were retained if they had continuous
eligibility, at least two OA diagnoses, OA drug use during the
observation period, no cancer, HIV or organ transplant, and were
not in a nursing home. The percentage of days of drug availabil-
ity, proportion of patients and cost were evaluated by type of pain
treatment and adjunctive therapy (i.e., ulcer medications, hyp-
notics, and antidepressants). Patients’ treatments were assessed
at the ﬁrst quarter and followed through the tenth quarter.
Random coefﬁcient models for utilization and cost outcomes were
evaluated, by treatment, using mixed model analysis of variance.
RESULTS: Eligible patients (N = 9972) were, on average, 55.1
years old (SD 9.7) and 65.6% were female. Common comor-
bidities included endocrine or immunity disorders (71.9%),
hypertension (59.0%), and obesity (17.6%). At the end of 30
months, the percent change in the number of subjects using COX-
2s and NSAIDs indicated a reduction of 76% and 10%, respec-
tively. Individual growth models on utilization and cost for
COX-2 (p < 0.001) conﬁrmed the trend. Among NSAID users,
35% used 2 or more different NSAIDs and 18.1% of these had
an average time between NSAID switches of 90 days or less. Nar-
cotics showed a signiﬁcant increasing trend in percentage of days
use and costs (p < 0.001). CONCLUSION: Trends over 30
months suggest, increasing narcotic use, high discontinuation of
COX-2s, and a high proportion of NSAID patients with switches
within 90 days. No single dominant therapy over time appeared
in this study suggesting there is a potential for new approaches
and reconsiderations for OA treatment.
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OBJECTIVES: While health care providers ﬁnd PRO data valu-
able for managing patients’ care, they also see a need for more
patient involvement. This research was conducted to gather
input from patients and providers about the value of health out-
comes data for patients in the area of rheumatoid arthritis with
or without psoriasis. METHODS: We conducted follow-up tele-
phone interviews with a sample of 50 individuals (27 physicians,
11 nurses, 12 patients) who participated in one of two programs
associated with rheumatoid arthritis. The programs were
designed to provide patient feedback about experiences with a
given prescription medication to physicians via one-page graph-
ical reports. The semi-structured interviews included questions
regarding providers’ impressions of the feedback and its value
for patients. Patients were asked about the program and the
value of feedback for them. This qualitative analysis summarizes
their responses. RESULTS: Of the 27 physicians interviewed,
56% (n = 15) were dermatologists and 44% (n = 12) rheuma-
tologists. Eleven nurses from dermatology practices and 12
patients with rheumatoid arthritis were interviewed as well. Par-
ticipants were in general agreement that the feedback was useful
for monitoring patients’ responses to treatment, when viewed in
conjunction with clinical observations. Many providers stated
that they could show the feedback to the patient, “in black and
white”, and begin a discussion. Most patients report participat-
ing in the programs because they want their physicians to receive
the feedback. Many patients also expressed an interest in receiv-
ing the feedback themselves to track their progress, indepen-
dently and relative to other patients. A few physicians echoed
this sentiment, stating that through the feedback patients could
feel connected and that may increase involvement in their care.
Providers however, emphasized that the information be provided
in “patient-friendly” terms. CONCLUSION: Based on this
research, a new audience for health outcomes data—delivered in
simple, straightforward terms—is patients themselves.
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OBJECTIVES: Assess impact of high patient out-of-pocket
expenditures (OOP) on adherence and persistence with biolog-
ics for treatment of RA. METHODS: An incidence cohort of RA
patients with pharmacy claims for etanercept or adalimumab
during 2002–2003 was selected from a database of insurance
claims from self-insured employer health plans (N = 2311).
Adherence was deﬁned as the medication possession ratio
(MPR), proportion of the 365 days follow-up covered by days
supplied. Persistence was determined using a survival analysis of
the likelihood of discontinuing therapy. Patient’s OOP was mea-
sured in two ways: 1) patient’s coinsurance and co-payments per
week of therapy, and 2) proportion of the biologic medication’s
cost paid by patient. Multivariate linear regression models of
MPR and proportional hazard models of persistence estimated
the impact of cost, adjusting for insurance type and demographic
and clinical variables. RESULTS: OOP expenditure averaged $8
per week (SD $14, range $0 to $127). Only a very small pro-
portion of patients (3.9%) paid more than $50 per week. The
mean (SD) MPR for all patients was 0.52 (0.31). Adherence sig-
niﬁcantly decreased with increased weekly OOP (Coeff −0.0035,
P < 0.0001) and when patients paid a higher proportion of
therapy costs (Coeff −0.8890, P < 0.0001). This translates into
approximately one week of therapy lost for every $5.50 increase
in weekly OOP. Adherence was lower for younger patients,
women and those with more comorbidities. Patients whose
